MENLO PARK, CA--(Marketwire - May 01, 2008) - Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that its lead selective GR-II antagonist, CORT 108297, produced promising results in a human microdosing study. “The compound was extremely well absorbed, demonstrated good bioavailability and had a half-life that appears compatible with once-a-day oral dosing in this ‘first-in-man’ study,” said Robert Roe, M.D., President of Corcept Therapeutics. Corcept had previously announced its discovery of three series of structurally different compounds that are potent blockers of the cortisol receptor but do not block the progesterone or any of the other steroid receptors in in vitro assays. “These microdosing results increase our confidence that we will be able to develop cortisol antagonists that are not abortifacients,” continued Dr. Roe.
